Blocking the binding of Aβ and apoE as a novel therapeutic approach for AD

阻断 Aβ 和 apoE 的结合作为 AD 的新型治疗方法

基本信息

批准号：
10621848
负责人：
THOMAS M WISNIEWSKI
金额：
$ 51.45万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10621848
关键词：
3xTg-AD mouse APP-PS1 Abeta synthesis Affect Alleles Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease pathology Amino Acids Amyloid Amyloid beta-Protein Amyloid deposition Antibodies ApoE knockout mouse Apolipoprotein E Binding Biochemical Biochemistry Biological Blood - brain barrier anatomy Blood Vessels Brain Cells Cerebral Amyloid Angiopathy Chimera organism Cholesterol Custom Data Analytics Databases Development Drug Kinetics Drug Targeting Ensure Geometry Human Immunotherapy In Vitro Knock-in Knock-in Mouse Knock-out Late Onset Alzheimer Disease Lead Libraries Ligand Binding Location Magnetic Resonance Imaging Mediating Mole the mammal Mus Neurons Parents Pathogenesis Pathologic Pathology Pathway interactions Peptides Peptoids Periodicity Permeability Pharmaceutical Chemistry Pharmaceutical Preparations Phenylalanine Plasma Process Proteome Proteomics Resistance Safety Senile Plaques Structure Synapses Techniques Testing Toxic effect Transgenic Organisms Treatment Efficacy abeta accumulation aged amyloid pathology antagonist apolipoprotein E-3 apolipoprotein E-4 behavioral study blood-brain barrier penetration data integration design dosage drug-like compound experimental study genetic risk factor human tissue improved in silico in vivo in vivo evaluation inhibitor innovation insight microCT microPET neuroinflammation novel novel strategies novel therapeutic intervention receptor response scaffold screening self assembly small molecule tau Proteins therapeutic effectiveness transgenic model of alzheimer disease treatment effect β-amyloid burden

项目摘要

PROJECT 2- SUMMARY/ABSTRACT The pathological accumulation of Aβ peptides as toxic oligomers, amyloid plaques and cerebral amyloid angiopathy (CAA), either from increased production of Aβ peptides or from their inadequate clearance, is critical in the pathogenesis of Alzheimer’s disease (AD). The apolipoprotein E4 (apoE4) allele, a major genetic risk factor for late-onset AD, was strongly associated with increased amyloid plaque and vascular amyloid pathology. We have shown that using Aβ12-28P peptides to block the apoE/Aβ interaction constitutes a novel treatment for AD by reducing brain parenchymal and vascular amyloid burden as well as tau -related pathology in multiple AD transgenic (Tg) lines. We also showed that Aβ12-28P penetrates the blood-brain-barrier (BBB). In our preliminary studies, we designed a peptoid library derived from the Aβ12 -28P sequence to screen for apoE/Aβ binding inhibitors with higher efficacy and safety compared to Aβ12-28P. Cyclic peptoids typically have better cell permeability compared to the linear peptides of the same or similar sequence. Indeed, our lead peptoid CPO_Aβ17-21P is cyclic, has a Ki of 1.02 nM against the binding of apoE4 and Aβ, and has therapeutic efficacy in an APP/PS1 AD Tg model. Our preliminary experiments clearly show it is highly effective at reducing the amyloid burden at a dosage 7.5-fold lower than that used with the parent Aβ12-28P. CPO_Aβ17-21P is therefore an outstanding starting point for further biochemical and medicinal chemistry development of both novel peptoid and drug-like, small molecules. We propose testing our lead small, BBB- penetrant, peptoid molecule and analogous drug-like, small molecules in vivo, hypothesizing that these will reduce both neuronal and synaptic toxicity by inhibiting the apoE4/Aβ interaction. We will investigate how these treatments affect the amyloid proteome, and correlate changes to findings in human tissue ( Project 1) and the proteome in the same AD Tg models after immunotherapy (Project 3). We hypothesize that the treated amyloid proteome in apoE4 mice will convert to a more apoE3-like proteome. Aim 1: Design non-toxic, pharmacokinetically favorable peptoid and drug-like, small molecule antagonists of the apoE/Aβ interaction, and characterize their effects in vitro. Aim 2: Te st the lead peptoid and analogous drug -like, small molecules in vivo using 3xTg mice, APP/PS1 and TgSwDI mice crossed onto human knock-in (KI) apoE2, E3 or E4, or apoE knock-out (KO) backgrounds. Aim 3: Compare the amyloid plaque and vessel proteomes in peptoid and drug-like, small molecule tre ated Tg and control mice on KI apoE2, E3 or E4, or apoE KO backgrounds .

项目 2-总结/摘要 Aβ肽以有毒低聚物、淀粉样蛋白斑和脑淀粉样蛋白的形式病理性积累血管病（CAA），无论是由于 Aβ 肽的产生增加还是由于其清除不足，载脂蛋白 E4 (apoE4) 等位基因在阿尔茨海默病 (AD) 的发病机制中至关重要。迟发性 AD 的危险因素，与淀粉样斑块和血管淀粉样蛋白的增加密切相关我们已经证明，使用 Aβ12-28P 肽来阻断 apoE/Aβ 相互作用构成了一种新的方法。通过减少脑实质和血管淀粉样蛋白负荷以及 tau 相关病理来治疗 AD 在多个 AD 转基因 (Tg) 系中，我们还发现 Aβ12-28P 可以穿透血脑屏障 (BBB)。在我们的初步研究中，我们设计了一个源自 Aβ12 -28P 序列的类肽文库来筛选与 Aβ12-28P 相比，apoE/Aβ 结合抑制剂通常具有更高的功效和安全性。与相同或相似序列的线性肽相比，具有更好的细胞渗透性。事实上，我们的领先产品。类肽 CPO_Aβ17-21P 是环状的，针对 apoE4 和 Aβ 的结合具有 1.02 nM 的 Ki，并且具有我们的初步实验清楚地表明它在 APP/PS1 AD Tg 模型中具有很高的治疗效果。与母体 Aβ12-28P 相比，剂量低 7.5 倍，即可有效减少淀粉样蛋白负荷。因此，CPO_Aβ17-21P 是进一步生物化学和药物化学的杰出起点我们建议测试我们的先导小分子 BBB- 的开发。体内渗透剂、类肽分子和类似药物的小分子，假设这些将我们将研究如何通过抑制 apoE4/Aβ 相互作用来减少神经元和突触毒性。这些治疗会影响淀粉样蛋白组，并将变化与人体组织中的发现相关联（项目 1）以及免疫治疗后相同 AD Tg 模型中的蛋白质组（项目 3）。 apoE4 小鼠中的淀粉样蛋白组将转化为更像 apoE3 的蛋白质组。目标 1：设计无毒、药代动力学有利的类肽和药物样小分子 apoE/Aβ 相互作用的拮抗剂，并表征其体外作用。目标 2：使用 3xTg 小鼠在体内测试先导肽和类似药物小分子， APP/PS1 和 TgSwDI 小鼠与人类敲入 (KI) apoE2、E3 或 E4 或 apoE 敲除 (KO) 杂交背景。目标 3：比较类肽和类药物小分子中的淀粉样蛋白斑和血管蛋白质组在 KI apoE2、E3 或 E4 或 apoE KO 背景下处理 Tg 和对照小鼠。